Home
Collaborations & Licensing in the Pharma & Biotech Industries
26 April - 27 April 2004
Collaborations & Licensing in the Pharma & Biotech Industries
Hear from experienced professionals:
· Dr Gary Cupit, Vice President, Global Business Development & Licensing, Novartis
· Dr Lauren Silverman, Director, Licensing & Development, Pfizer
· Dr Ray Hill, Executive Director, Licensing & External Research, Europe, Merck
· Dr Adrian Carter, Senior Project Leader, Licensing & Contract Management, Boehringer Ingelheim
· Dr Wolfgang Schmidt, Scientific Affairs, Aventis
· Jürgen Heitmann, Head, Search & Evaluation, Novartis
· Dr Jonathan Turner, Head, Corporate Department, Business Development, Boehringer Ingelheim
· Onno Van de Stolpe, Chief Executive Officer, Galapagos Genomics
· Andrew Mackie, Head, Alliance Management, Antisoma
· Oliver Gandy, Legal Adviser, Pfizer

A comprehensive event where you will hear about:
· CHOOSING THE RIGHT PARTNER: Identify the key attributes
· LICENSING DEALS: Create better opportunities
· DEAL-MAKING: Evaluate the benefits of early and late stage deals
· UNDERSTANDING OF VALUE: Understanding through negotiation
· BEST PRACTICE APPROACH: Get to grips with the practicalities of joint ventures in the Pharma & Biotech industries
· THE COMMERCIAL ENVIRONMENT: Assess the influence of the market on collaborations

Conference agenda

clock

8:30

Registration and Coffee

clock

9:00

Registration and Coffee

clock

9:00

Defining the role of alliance management

  • What does the alliance landscape look like?
  • How do companies structure and organise their alliance management efforts?
  • What purpose does alliance management serve?
  • What does this mean for the alliance manager?
  • clock

    9:30

    Introductions & objectives

    clock

    10:00

    Overview of the Biotech and Pharma environment (key drivers to collaborate)

    clock

    10:00

    Structuring and launching a collaboration

  • Governance structure and process
  • Performance measurement
  • Integration of partners’ processes
  • Implementation of the collaboration
  • clock

    10:30

    Due Diligence

    clock

    11:00

    Morning Coffee

    clock

    11:15

    Morning Coffee

    clock

    11:30

    How do you know you are getting a good deal?

    clock

    11:30

    Operational issues in managing alliances

  • Understanding risks
  • Launching the alliance
  • Managing change
  • Understanding partners’ perceptions
  • clock

    12:15

    Discussion – review of session, questions & answers

    clock

    12:30

    Networking Lunch

    clock

    12:30

    Close of Executive Briefing

    clock

    14:00

    Post-deal implementations

    clock

    15:00

    Managing alliances effectively internally (case study)

    clock

    16:00

    Discussion – review of session, questions and answers

    clock

    16:15

    Close of Executive Briefing

    clock

    8:30

    Registration and Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Dr Jim Phillips

    Dr Jim Phillips, Chief Executive Officer, Bone Medical & Diabetology

    clock

    9:10

    TRENDS AFFECTING THE FUTURE OF DRUG DEVELOPMENT & COMMERCIALIZATION

    Dr Gary Cupit

    Dr Gary Cupit, Vice President, Global Business Development & Licensing, Novartis

  • Development of therapeutic agents for commercialisation has greater financial pressures
  • Emerging, fully integrated Biotechs are competing with Big Pharma for assets
  • Decreasing competitive life cycles, more complex FDA reviews, pricing and reimbursement concerns and the influence of consumer marketing have driven costs higher than anticipated
  • Assumptions in planning for sales, marketing and regulatory review must be challenged
  • Global markets are evolving at different rates influenced by economic as well as regulatory changes
  • clock

    9:40

    PARTNER PROCESS

    Dr Lauren Silverman

    Dr Lauren Silverman, Director, Licensing & Development, Pfizer

  • What are the risks associated with finding the right partner?
  • Companies positioning themselves as ‘partner of choice’
  • Identify key attributes in your partner
  • Align corporate culture
  • Strike a win-win agreement
  • Partnering strategies of the future
  • clock

    10:20

    BUILDING PARTNERSHIPS

    Andrew Mackie

    Andrew Mackie, Head, Alliance Management, Antisoma

  • The evolving and interdependence on Pharma
  • Partnering pitfalls and collaboration catastrophes
  • Adding mutual value through partnerships
  • Competition for partnering
  • early detection and prevention of conflicts
  • clock

    11:00

    Morning Coffee

    clock

    11:20

    WHY COMPETITIVE INTELLIGENCE IS FUNDAMENTAL TO LICENSING DEALS & COLLABORATIVE ARRANGEMENTS

    Richard Withers

    Richard Withers, Managing Director, Europe, Fuld & Co.

  • What is CI and how is it commonly applied in the Life Sciences industry?
  • How CI can help spot opportunities – case study
  • How CI can help filter opportunities – case study
  • How CI can help negotiations with opportunities – case study
  • How CI can help new entities – case study
  • What does CI cost?
  • clock

    12:00

    INTEGRATED LICENSING

    Kevin Quinn

    Kevin Quinn, Manager, Business Planning & Information, Helsinn Healthcare

  • Integrated licensing: definition, role and partnership approaches
  • Case study: the successful integrated licensing of palonosetron to MGI Pharma for North America
  • Key issues for win-win partnerships with integrated licensing companies
  • clock

    12:40

    Networking Lunch

    clock

    14:00

    EFFECTIVE LICENSING & COLLABORATIONS

    Dr Anne Bruinvels

    Dr Anne Bruinvels, Chief Executive Officer, Curidium

  • Building Biotech companies through strategic deal-making
  • Effective partnerships in research and development
  • The right partner: Pharma vs Biotech
  • Creating opportunities for successful licensing deals
  • R&D capabilities important to reinforcing development pipelines
  • Deal-making and making deals work
  • clock

    14:40

    MANAGING THE DEAL-MAKING PROCESS

    Dr Adrian Carter

    Dr Adrian Carter, Senior Project Leader, Licensing & Contract Management, Boehringer Ingelheim

  • Formulating strategy based on existing franchise
  • Locating the appropriate opportunity by screening and evaluation
  • Investigating product specifications and forecasting value
  • Negotiating for a common understanding of value
  • Integrating the deal to realise value
  • clock

    15:20

    Afternoon Tea

    clock

    15:40

    CREATING A STRATEGY

    Jürgen Heitmann

    Jürgen Heitmann, Head, Search & Evaluation, Novartis

  • Why strategy is so important to successful licensing
  • Identifying strategic gaps and opportunities
  • Differentiating yourself as the partner of choice
  • Aligning licensing strategies with other line functions
  • Successful and efficient screening for strategic targets
  • clock

    16:20

    ALLIANCE MANAGEMENT ALONG THE VALUE CHAIN

    Dr Wolfgang Schmidt

    Dr Wolfgang Schmidt, Scientific Affairs, Aventis

  • Types of alliances
  • Tools and processes
  • Effective project management
  • Portfolio management and alignment to strategy
  • Biotech and relationship with partners
  • Build up and extension of scientific networks
  • clock

    17:00

    Chairman’s Closing Remarks and Close of Day One

    clock

    8:30

    Re-registration and Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Michael Stone

    Michael Stone, Of Counsel, Covington & Burling

    clock

    9:10

    DEAL-MAKING AND FORWARD INTEGRATION

    Paul de Potocki

    Paul de Potocki, Senior Vice President, Commercial Operations, Biovitrum

  • Development of the Biotech business model
  • Alignment of company and partnership strategy
  • Partnering process and key deal parameters - the Biotech perspective
  • Achieving objectives for strategic development and forward integration
  • clock

    9:40

    TRENDS IN DEAL-MAKING

    Dr Ignacio Faus Santasusana

    Dr Ignacio Faus Santasusana, Director, Business Development & Licensing, Grupo Uriach

  • Partnerships through co-marketing rights
  • How are committees set up to manage partnering transactions?
  • Early stage in-licensing
  • Investment in technology
  • Value and importance of licensing
  • Assessing regulatory requirement due to development risk
  • clock

    10:20

    INTELLECTUAL PROPERTY DUE DILLIGENCE

    Dr David Harper, Partner, McDonnell, Boehnen, Hulbert & Berghoff

  • Ownership
  • Licensed rights
  • Claim scope
  • Patentability and patent validity
  • Freedom to operate
  • Related issues
  • clock

    11:00

    Morning Coffee

    clock

    11:20

    BEST APPROACH TO STRUCTURE LICENSING DEALS

    Michael Stone

    Michael Stone, Of Counsel, Covington & Burling

    Jürgen Heitmann

    Jürgen Heitmann, Head, Search & Evaluation, Novartis

    Dr Anne Bruinvels

    Dr Anne Bruinvels, Chief Executive Officer, Curidium

    Oliver Gandy

    Oliver Gandy, Legal Adviser, Pfizer

    clock

    12:00

    STRATEGIC LICENSING AND ALLIANCE CAPABILITIES

    Dr Jonathan Turner

    Dr Jonathan Turner, Head, Corporate Department, Business Development, Boehringer Ingelheim

  • Adopting the best practice approach to portfolio
  • Management aiding the decision-making
  • Improvement of joint ventures
  • Sharing the workload
  • Stages of involvement for those approving deals
  • Deciding when to license and to obtain the best ROI
  • clock

    12:40

    Networking Lunch

    clock

    14:00

    WHY ARE COMPANIES IN-LICENSING TECHNOLOGY INSTEAD OF ACQUIRING A TECHNOLOGY COMPANY?

    Dr Ray Hill

    Dr Ray Hill, Executive Director, Licensing & External Research, Europe, Merck

  • Are Big Pharma dependant on in-licensed products?
  • Companies building strong pipelines
  • Successful licensing deals matched with strategy
  • Assessing the risks: what is the chance of delivering the promise?
  • Key advantages and disadvantages
  • clock

    14:40

    CONTRACTUAL AND INTELLECTUAL PROPERTY ISSSUES

    Oliver Gandy

    Oliver Gandy, Legal Adviser, Pfizer

  • The fear of contamination – managing confidentiality
  • Dividing up new intellectual property
  • Royalties, milestones and reach throughs
  • Diligence obligations and the need for control
  • Warranty and indemnity issues
  • Termination and reversionary rights
  • clock

    15:20

    Afternoon Tea

    clock

    15:40

    APPLICATION OF TAX EFFICIENT SUPPLY CHAIN MANAGEMENT FOR PHARMA & BIOTECH INDUSTRY

    Mehernosh Lentin

    Mehernosh Lentin, Director, OSM Consulting Partners (formerly Baxter)

  • The situation today
  • Industry drivers for Pharma and Biotech organisations
  • Evolution of a collaborative model - companies in-licensing technology instead of acquiring technology
  • Accessing technologies through alliances
  • Establishing a tax efficient model
  • Maximising corporate value while minimising financial risks and managing cash flows
  • clock

    16:20

    PLANNING FOR THE FUTURE

    Onno van de Stolpe

    Onno van de Stolpe, Chief Executive Officer, Galapagos Genomics

  • From idea to reality, from genomics platform to drug discovery
  • Identifying limitations to growth and success
  • Developing strategy for further growth and development
  • Structuring collaborative agreements
  • Optimising returns through complex deal terms
  • clock

    17:00

    Chairman's Closing Remarks and Close of Conference

    Workshops

    Finding the <i>Right</i> Pharma Partner

    Finding the Right Pharma Partner

    The Hatton, at etc. venues
    28 April 2004
    London, United Kingdom

    Managing Pharmaceutical & Biotechnology Collaborations

    Managing Pharmaceutical & Biotechnology Collaborations

    The Hatton, at etc. venues
    28 April 2004
    London, United Kingdom

    VENUE

    The Hatton, at etc. venues

    51/53 Hatton Garden, London, United Kingdom

    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
    HOTEL BOOKING FORM

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.